VIMIZIM (elosulfase alfa) injection

Vimzin (Elosulfase alfa)

VIMZIN

Elosulfase alfa

5 mg/5 mL (1 mg/mL) in single-dose vials

BioMarin Pharmaceutical Inc.

Medical Use

Vimizim (elosulfase alfa) is an enzyme that specifically targets and breaks down glycosaminoglycans (GAGs) within lysosomes. It is prescribed for individuals with Mucopolysaccharidosis type IVA (MPS IVA), also known as Morquio A syndrome.

Dosage Instructions: The advised dosage of Vimizim is 2 mg per kg of body weight, administered intravenously. The infusion should last between 3.5 to 4.5 hours, depending on the volume. This treatment is given once a week. It is recommended to take antihistamines, with or without antipyretics, 30 to 60 minutes before starting the infusion.